Explore 3 Stock Ideas & Industry Insights Download Free Report

888-969-2592
Shopping Cart 0
countryflagCA
Login

Home CompaniesMBX Biosciences, Inc. Common Stock

MBX Biosciences, Inc. Common Stock

Healthcare Biotechnology
PortfolioPortfolio WatchlistWatchlist
Company price
53.98 USD 2.63 ( 5.12%)
Last update at 2026-11-09T15:43:00Z
VOLUME
43372
Market Cap
2941.62M

Momentum Score

…

MBX Biosciences, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of precision peptide therapies for the treatment of endocrine and metabolic disorders. Its lead product candidate is Canvuparatide (MBX 2109), a parathyroid hormone peptide prodrug, which is in Phase 3 clinical trial for the treatment of chronic hypoparathyroidism. The company is also developing Imapextide (MBX 1416), a long-acting glucagon-like peptide-1 (GLP-1) receptor antagonist that is in Phase 2 clinical trial a potential therapy for post-bariatric hypoglycemia, a chronic complication of bariatric surgery. In addition, it is developing MBX 4291, a lead obesity product candidate, which is in investigational new drug-enabling studies for the treatment of obesity and co-morbidities. The company was founded in 2018 and is based in Carmel, Indiana.

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Day Price Range
51.95
Low
54.59
High
52 Week Price Range
9.66
Low
72.64
High

Momentum Score

…
Loading momentum score…

A unique technical analysis driven score developed by Kalkine showing momentum in stock prices based on select technical indicators identified.

Score - Rating
>= 1 - Low / > 1 but < 2 - Below Average / > 2 but < 3 - Average / > 3 but < 4 - Above Average / > 4 - High

Key Metrics*

Previous Close
51.35
Dividend Yield
-
Revenue TTM
0.00M
Revenue Per Share
-
Gross Profit TTM
0.00M
Debt / Equity
0.00
ROE
-33.17%
Net Debt
-74.69M
ROCE
-23.53%
Diluted EPS TTM
-2.37

Key Financials*

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31
Type yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31
Income before tax -86.97M -61.92M -32.56M -26.14M
Net income -86.97M -61.92M -32.56M -26.14M
Selling general administrative 18.90M 10.78M 6.78M 3.76M
Gross profit -0.25M -0.24M -0.16M -0.06M
Reconciled depreciation 0.25M 0.24M 0.16M 0.06M
Ebit -86.97M -61.92M -32.56M -25.76M
Ebitda -86.72M -61.68M -32.41M -25.70M
Depreciation and amortization 0.25M 0.24M 0.16M 0.06M
Operating income -98.06M -68.19M -35.31M -25.16M
Other operating expenses 98.06M 68.19M 35.31M 25.16M
Interest expense - - 0.00M 0.37M
Interest income 11.08M 6.27M 2.75M 0.37M
Net interest income 11.08M 6.27M 2.75M -0.00M
Total revenue 0.00M 0.00M 0.00M 0.00M
Total operating expenses 98.06M 68.19M 35.31M 25.16M
Cost of revenue 0.25M 0.24M 0.16M 0.06M
Total other income expense net 11.08M 6.27M 2.75M -0.97M
Net income from continuing ops -86.97M -61.92M -32.56M -26.14M
Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31
Type yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31
Total assets 385.14M 268.54M 84.18M 45.09M
Other current assets 5.71M 4.46M 2.58M 1.61M
Total liab 15.92M 11.09M 156.65M 87.70M
Total stockholder equity 369.22M 257.44M -72.47M -42.60M
Other current liab 12.35M 5.54M 2.38M 2.32M
Common stock 0.01M 0.01M 0.00M 0.00M
Capital stock 0.01M 0.01M 0.00M 0.00M
Retained earnings -224.48M -137.50M -75.58M -43.02M
Cash 75.29M 49.35M 30.52M 24.21M
Total current liabilities 15.49M 11.05M 3.93M 3.43M
Net debt -74.69M -49.18M -30.20M -23.75M
Short term debt 0.17M 0.17M 0.15M 0.14M
Short long term debt total 0.60M 0.17M 0.32M 0.46M
Other stockholder equity 593.41M 394.89M 3.05M 0.41M
Total current assets 381.54M 267.29M 83.47M 44.21M
Short term investments 298.42M 212.80M 50.15M 18.25M
Net receivables 2.12M 0.68M 0.21M 0.14M
Accounts payable 2.98M 5.33M 1.39M 0.98M
Accumulated other comprehensive income 0.29M 0.06M 0.06M 0.00M
Non currrent assets other 0.38M 0.05M 0.05M 0.04M
Non current assets total 3.60M 1.25M 0.71M 0.88M
Capital lease obligations 0.60M 0.17M 0.32M 0.46M
Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31
Type yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31
Investments -81.78M -160.59M -30.93M -11.41M
Total cashflows from investing activities -83.70M -160.59M -30.93M -11.41M
Net borrowings - - 0.00M 10.00M
Total cash from financing activities 189.59M 234.10M 69.22M 46.06M
Net income -86.97M -61.92M -32.56M -26.14M
Change in cash 25.94M 18.83M 6.31M 11.53M
Begin period cash flow 49.35M 30.52M 24.21M 12.68M
End period cash flow 75.29M 49.35M 30.52M 24.21M
Total cash from operating activities -79.95M -54.68M -31.98M -23.12M
Issuance of capital stock 187.95M 238.04M 68.51M 36.49M
Depreciation -3.61M 0.24M 0.16M 0.06M
Other cashflows from investing activities 8.50M - - -
Other cashflows from financing activities 189.59M 59.56M 68.48M 36.06M
Capital expenditures 1.93M 0.87M 0.13M 0.44M
Change in working capital 1.57M 4.60M -0.73M 1.29M
Stock based compensation 8.68M 5.22M 2.04M 0.31M
Other non cash items 0.38M -2.82M -0.88M 1.36M
Free cash flow -81.88M -55.55M -32.11M -23.56M

Peer Comparison*

Sector: Healthcare Industry: Biotechnology

Stock Name
Change
(USD)
Price
(USD)
Trailing
PE (x)
Forward
PE (x)
Price Sales
TTM (x)
Price to Book Value (x)
MBX
MBX Biosciences, Inc. Common Stock		 2.63
5.12%		 53.98 - - - 7.00
NVO
Novo Nordisk A/S		 0.47
1.18%		 40.78 41.58 31.15 2.13 32.99
VRTX
Vertex Pharmaceuticals Inc		 0.34
0.06%		 547.43 30.22 24.27 10.36 6.50
REGN
Regeneron Pharmaceuticals Inc		 8.76
0.97%		 913.11 29.07 20.12 7.57 3.82
ARGNF
argenx SE		 -
-%		 900.30 45.77 31.25 13.84 7.12

Profile*

MBX Biosciences, Inc. Common Stock

MBX Biosciences, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of precision peptide therapies for the treatment of endocrine and metabolic disorders. Its lead product candidate is Canvuparatide (MBX 2109), a parathyroid hormone peptide prodrug, which is in Phase 3 clinical trial for the treatment of chronic hypoparathyroidism. The company is also developing Imapextide (MBX 1416), a long-acting glucagon-like peptide-1 (GLP-1) receptor antagonist that is in Phase 2 clinical trial a potential therapy for post-bariatric hypoglycemia, a chronic complication of bariatric surgery. In addition, it is developing MBX 4291, a lead obesity product candidate, which is in investigational new drug-enabling studies for the treatment of obesity and co-morbidities. The company was founded in 2018 and is based in Carmel, Indiana.

11711 North Meridian Street, Carmel, IN, United States, 46032

317 659 0200

https://mbxbio.com

63

Name Title Year Born
Mr. Steven L. Hoerter Executive Chairperson, CEO & President 1971
Dr. Salomon Azoulay M.D. Chief Medical Officer 1958
Mr. John W. Smither CPA Chief Financial Officer 1953
Mr. Pete De Spain Senior Vice President of Investor Relations & Corporate Communications NA
Ms. Michelle Graham Chief Human Resources Officer 1967
Dr. Michael A. Dorato DABT, Ph.D. Sr. Vice President of Discovery & Non-Clinical Development NA
Dr. Chatan Charan Ph.D. Senior VP of Pharmaceutical Development & Chemistry, Manufacturing and Controls NA
Mr. Mark Hope Senior Vice President of Regulatory & Quality NA
Dr. Andreas Moraitis M.D. Senior Vice President of Clinical Development NA
Ms. Karen Basbaum M.B.A. Chief Business Officer NA

Disclaimer - (*)This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.

Kalkine

3 Mining Stock
Ideas Report

Download a free report with stock ideas and industry insights for general information.

Download Free Report Now → sector image

Top Stocks by Market Cap*

GFR
CAD 10.96
+38.15%
MOON
CAD 4.83
+9.64%
PDN
CAD 8.13
+7.68%
BDT
CAD 72.82
+6.65%
HG
CAD 4.28
+6.20%
CSU
CAD 3300.00
-6.42%
CURA
CAD 12.68
-4.16%
DIV
CAD 3.93
-3.44%
SOIL
CAD 7.18
-3.10%
OBE
CAD 13.31
-2.92%

Equity Sectors*

  • Basic Materials

    +3.63%

  • Communication Services

    -1.14%

  • Consumer Cyclical

    +0.75%

  • Consumer Defensive

    -0.36%

  • Energy

    +2.18%

  • Financial Services

    +1.33%

  • Healthcare

    +1.49%

  • Industrials

    +2.99%

  • Real Estate

    +0.41%

  • Technology

    +1.45%

  • Utilities

    +1.09%

Note: Daily price change (%) by sector excluding stocks with +/-90% daily price change. Companies above $500 million market capitalization are considered.

Support

Hi! How can we help you today?

Loading…